Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors

Musaffe Tuna; Christopher I. Amos; Gordon B. Mills

doi:10.18632/oncotarget.26777

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors

Musaffe Tuna _, Christopher I. Amos and Gordon B. Mills

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2019; 10:2095-2111. https://doi.org/10.18632/oncotarget.26777

Metrics: PDF 2624 views | Full Text 7313 views | ?

Abstract

Musaffe Tuna1,2, Christopher I. Amos2,3 and Gordon B. Mills4,5,6

1Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Department of Medicine, Baylor College of Medicine, Houston, TX, USA

3Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA

4Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health Science University, Portland, OR, USA

6Precision Oncology, Knight Cancer Institute, Portland, OR, USA

Correspondence to:

Musaffe Tuna, email: [email protected]

Keywords: fusion genes; fusion transcripts; epithelial tumors; mechanisms; pathobiology

Received: November 14, 2018 Accepted: February 22, 2019 Published: March 12, 2019

ABSTRACT

Recurrent fusion transcripts, which are one of the characteristic hallmarks of cancer, arise either from chromosomal rearrangements or from transcriptional errors in splicing. DNA rearrangements include intrachromosomal or interchromosomal translocation, tandem duplication, deletion, inversion, or result from chromothripsis, which causes complex rearrangements. In addition, fusion proteins can be created through transcriptional read-through. Fusion genes can be transcribed to fusion transcripts and translated to chimeric proteins, with many having demonstrated transforming activities through multiple mechanisms in cells. Fusion proteins represent novel therapeutic targets and diagnostic biomarkers of diagnosis, disease status, or progression. This review focuses on the mechanisms underlying the formation of oncogenic fusion genes and transcripts and their impact on the pathobiology of epithelial tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26777

Publication Alerts

Post-Publication Promotion

Reviews:

Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors

Abstract